Related references
Note: Only part of the references are listed.The launch of opicapone for Parkinson's disease: negatives versus positives
Ana Castro Caldas et al.
EXPERT OPINION ON DRUG SAFETY (2018)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine
Margherita Fabbri et al.
MOVEMENT DISORDERS (2018)
Safety and Efficacy of Tolcapone in the Long-term Use in Parkinson Disease: An Observational Study
Karla Eggert et al.
CLINICAL NEUROPHARMACOLOGY (2014)
Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition
Siegfried Muhlack et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
Tolcapone addition improves Parkinson's disease associated nonmotor symptoms
Thomas Mueller
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2014)
Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Tolcapone improves sleep in patients with advanced Parkinson's disease (PD)
Georg Ebersbach et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS (2010)
Replacing a Dopamine Agonist by the COMT-Inhibitor Tolcapone as an Adjunct to L-dopa in the Treatment of Parkinson's Disease: A Randomized, Multicenter, Open-Label, Parallel-Group Study
Vincent Ries et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Quality of Life in Parkinson's Disease Patients Following Adjunctive Tolcapone Therapy: Results of an Open-Label, Multicenter, Community-Based Trial
Kapil Sethi et al.
CNS SPECTRUMS (2010)
Tolcapone in elderly patients with Parkinson's disease: A prospective open-label multicenter non-interventional trial
Georg Ebersbach et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Clinical experience of tolcapone in advanced Parkinson's disease
Margherita Canesi et al.
NEUROLOGICAL SCIENCES (2008)
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
A. J. Lees et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease
Esko Kinnunen et al.
MOVEMENT DISORDERS (2007)
Tolcapone: An efficacy and safety review (2007)
C. Warren Olanow et al.
CLINICAL NEUROPHARMACOLOGY (2007)
Results from a 2-year centralized tolcapone liver enzyme monitoring program
Mark F. Lew et al.
CLINICAL NEUROPHARMACOLOGY (2007)
F-18-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
R Ceravolo et al.
SYNAPSE (2002)
Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations
W Koller et al.
MOVEMENT DISORDERS (2001)
Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease
SA Factor et al.
CLINICAL NEUROPHARMACOLOGY (2001)
Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD
O Suchowersky et al.
CLINICAL NEUROPHARMACOLOGY (2001)
Switch-over from tolcapone to entacapone in severe Parkinson's disease patients
M Onofrj et al.
EUROPEAN NEUROLOGY (2001)
Heart rate variability in Parkinson's disease patients treated with tolcapone
G Meco et al.
PARKINSONISM & RELATED DISORDERS (2000)
Share Paper
